查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1637030

重症肌無力治療市場 - 全球產業分析、規模、佔有率、成長、趨勢及 2032 年預測

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 230 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球重症肌無力 (MG) 治療市場預計將顯著成長，複合年增長率為 8.2%。預計市場規模將從 2025 年的 26.9 億美元飆升至 2032 年的 46.7 億美元。這種上升趨勢是由治療技術的進步和對重症肌無力的認識的提高所推動的。

重症肌無力 (MG) 是一種神經肌肉自體免疫疾病，由於神經和肌肉之間的交流受損而導致肌肉無力和疲勞。治療的主要目標是增強神經肌肉傳遞和抑制自體免疫活動。可用的治療策略包括乙醯膽鹼酯酶抑制劑、免疫抑制劑和創新單株抗體療法。

重症肌無力盛行率不斷上升（尤其是在老年族群）以及人們對精準醫療的興趣日益濃厚是推動市場擴張的主要因素。此外，透過製藥公司和研究機構的聯合研究，下一代標靶治療藥物的開發正在快速進展。

依庫珠單抗和利妥昔單抗等單株抗體透過針對特定的免疫成分徹底改變了 MG 治療，從而實現了更有效的疾病管理。免疫療法的不斷進步增強了我們應對複雜免疫因素的能力，並提供更精確、更有效的治療選擇。

本報告研究了全球重症肌無力治療市場，並概述了市場狀況、藥物類別、分銷管道和地區的趨勢，以及參與市場的公司的競爭動態。

目錄

第1章 執行摘要

第2章 市場概況

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • COVID-19 影響分析
  • 烏克蘭與俄羅斯衝突的影響
  • 經濟概況
  • PESTLE分析

第3章 2019 年至 2032 年全球重症肌無力治療市場展望

  • 2019 年至 2032 年全球重症肌無力治療市場預測（按藥物類別、價值（十億美元））
  • 2019 年至 2032 年全球重症肌無力治療市場預測（按分銷管道劃分）價值（十億美元）
  • 2019 年至 2032 年全球重症肌無力治療市場預測（按地區劃分）價值（十億美元）

第4章 2019 年至 2032 年北美重症肌無力治療市場展望

第5章 2019 年至 2032 年歐洲重症肌無力治療市場展望

第6章 亞太地區重症肌無力治療市場展望，2019-2032 年

第7章 2019 年至 2032 年拉丁美洲重症肌無力治療市場展望

第8章 中東和非洲重症肌無力治療市場展望，2019 - 2032 年

第9章 競爭格局

  • 2025 年企業市佔率分析
  • 比賽儀表板
  • 公司簡介
    • Grifols SA
    • Pfizer, Inc.
    • AbbVie Inc.
    • GSK
    • Novartis AG
    • Alexion Pharmaceutical Inc.
    • F. Hoffman-La Roche Ltd.
    • Bausch Health Companies Inc.
    • Shire plc.
    • Avadel Pharmaceuticals plc.

第 10 章 附錄

簡介目錄

The global myasthenia gravis (MG) treatment market is poised for substantial growth, with projections indicating an 8.2% compound annual growth rate (CAGR). The market size is expected to surge from USD 2.69 billion in 2025 to USD 4.67 billion by 2032. This upward trajectory is fueled by technological advancements in treatment methodologies and rising awareness about MG.

Overview of Myasthenia Gravis and Treatment Approaches

Myasthenia gravis (MG) is a neuromuscular autoimmune disorder that leads to muscle weakness and fatigue due to disrupted communication between nerves and muscles. The primary goal of treatment is to enhance neuromuscular transmission and suppress autoimmune activity. Available therapeutic strategies include acetylcholinesterase inhibitors, immunosuppressive drugs, and innovative monoclonal antibody therapies.

The increasing prevalence of MG, particularly among the aging demographic, and the growing focus on precision medicine are key drivers of market expansion. Moreover, collaborations between pharmaceutical companies and research institutions are fast-tracking the development of next-generation targeted treatments.

Key Market Growth Drivers

1. Breakthroughs in Immunotherapy

  • Monoclonal antibodies, such as eculizumab and rituximab, are revolutionizing MG treatment by targeting specific immune components, leading to more effective disease management.
  • Ongoing advancements in immunotherapy are enhancing the ability to address complex immunological factors, providing more precise and effective treatment options.

2. Increasing Awareness and Early Diagnosis

  • Enhanced diagnostic tools and public health initiatives are facilitating earlier detection of MG, improving patient outcomes.
  • Greater recognition among healthcare professionals and public awareness campaigns are boosting demand for effective treatment solutions.

Emerging Business Opportunities

1. Expansion of Personalized Treatment Strategies

  • Precision medicine is reshaping MG treatment by customizing therapies based on individual genetic profiles. This approach enhances treatment efficacy and minimizes side effects.
  • Advancements in immunogenetics and biotechnology are fostering the development of personalized therapeutic solutions.

2. Innovation in Treatment Modalities

  • Companies exploring new treatment avenues, such as gene therapies and advanced immunomodulators, have the potential to address unmet medical needs and unlock new revenue opportunities.
  • The adoption of next-generation biologics and novel drug formulations is reshaping the competitive Analysisof MG treatment.

Regional Market Insights

1. Europe: A Hub for Advanced MG Treatments

  • Europe leads the market due to its robust healthcare infrastructure and supportive regulatory framework.
  • Cutting-edge diagnostic facilities and specialized neurological care centers are driving rapid adoption of advanced MG treatments.
  • The European Medicines Agency's (EMA) proactive policies bolster investment confidence and accelerate drug development initiatives.

2. South Asia & Pacific: Fastest-Growing Market

  • Rapid population growth, along with an increasing prevalence of MG, is fueling demand for effective treatment solutions in this region.
  • Expanding healthcare access, coupled with rising awareness campaigns, is encouraging early diagnosis and treatment adoption.

Market Challenges and Barriers

1. Regulatory Hurdles

  • Stringent approval processes for new MG drugs can delay market entry, making regulatory compliance a critical challenge for pharmaceutical firms.
  • Companies must navigate complex approval requirements to maintain a competitive edge.

2. Complexity of MG Treatment

  • Due to MG's heterogeneous nature, treatment protocols must be personalized, making standardization difficult.
  • The need for individualized treatment plans increases the complexity of drug development and clinical trials.

Competitive Landscape: Key Industry Players

Several leading pharmaceutical companies are actively engaged in developing and commercializing MG treatments, including:

  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc

These companies are investing in research and development (R&D) to introduce next-generation therapies and expand their market presence.

Market Segmentation: Key Categories

1. By Drug Class

  • Cholinesterase Inhibitors
  • Corticosteroids
  • Immunosuppressants
  • Intravenous Immunoglobulin (IVIg)
  • Monoclonal Antibodies

2. By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

3. By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Myasthenia Gravis Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 3.1. Global Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Corticosteroids
      • 3.1.1.2. IVIg
      • 3.1.1.3. Monoclonal Antibodies
      • 3.1.1.4. Immunosuppressants
      • 3.1.1.5. Cholinesterase Inhibitors
  • 3.2. Global Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Retail Pharmacies
      • 3.2.1.3. Online Pharmacies
  • 3.3. Global Myasthenia Gravis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 4.1. North America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Corticosteroids
      • 4.1.1.2. IVIg
      • 4.1.1.3. Monoclonal Antibodies
      • 4.1.1.4. Immunosuppressants
      • 4.1.1.5. Cholinesterase Inhibitors
  • 4.2. North America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Retail Pharmacies
      • 4.2.1.3. Online Pharmacies
  • 4.3. North America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 4.3.1.2. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 4.3.1.3. Canada Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 4.3.1.4. Canada Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 5.1. Europe Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Corticosteroids
      • 5.1.1.2. IVIg
      • 5.1.1.3. Monoclonal Antibodies
      • 5.1.1.4. Immunosuppressants
      • 5.1.1.5. Cholinesterase Inhibitors
  • 5.2. Europe Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Retail Pharmacies
      • 5.2.1.3. Online Pharmacies
  • 5.3. Europe Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.2. Germany Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.3. U.K. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.4. U.K. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.5. France Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.6. France Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.7. Italy Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.8. Italy Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.9. Turkey Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.10. Turkey Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.11. Russia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.12. Russia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.13. Rest of Europe Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.14. Rest of Europe Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 6.1. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Corticosteroids
      • 6.1.1.2. IVIg
      • 6.1.1.3. Monoclonal Antibodies
      • 6.1.1.4. Immunosuppressants
      • 6.1.1.5. Cholinesterase Inhibitors
  • 6.2. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Retail Pharmacies
      • 6.2.1.3. Online Pharmacies
  • 6.3. Asia Pacific Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.2. China Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.3. Japan Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.4. Japan Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.5. South Korea Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.6. South Korea Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.7. India Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.8. India Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.9. Southeast Asia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.10. Southeast Asia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.11. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.12. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 7.1. Latin America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Corticosteroids
      • 7.1.1.2. IVIg
      • 7.1.1.3. Monoclonal Antibodies
      • 7.1.1.4. Immunosuppressants
      • 7.1.1.5. Cholinesterase Inhibitors
  • 7.2. Latin America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Retail Pharmacies
      • 7.2.1.3. Online Pharmacies
  • 7.3. Latin America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.2. Brazil Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.3. Mexico Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.4. Mexico Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.5. Argentina Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.6. Argentina Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.7. Rest of Latin America Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.8. Rest of Latin America Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 8.1. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Corticosteroids
      • 8.1.1.2. IVIg
      • 8.1.1.3. Monoclonal Antibodies
      • 8.1.1.4. Immunosuppressants
      • 8.1.1.5. Cholinesterase Inhibitors
  • 8.2. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Retail Pharmacies
      • 8.2.1.3. Online Pharmacies
  • 8.3. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.2. GCC Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.3. South Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.4. South Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.5. Egypt Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.6. Egypt Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.7. Nigeria Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.8. Nigeria Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.9. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.10. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2025
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Grifols SA
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Pfizer, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. AbbVie Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. GSK
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. Novartis AG
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Alexion Pharmaceutical Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. F. Hoffman-La Roche Ltd.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Bausch Health Companies Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Shire plc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. Avadel Pharmaceuticals plc.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations